NCT00403559

A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis

A 4 Week Randomized Double-blind Parallel Group Active Comparator Controlled Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 113 (actual)
• Sponsor: Dermatology Specialists Research · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This is an exploratory study to determine effectiveness of Elidel for the treatment of seborrheic dermatitis

Detailed description

This is a 4 week study for patients 18 and older to compare the efficacy and safety of pimecrolimus cream 1% twice daily and ketaconazole cream 2 % twice daily for the treatment of seborrheic dermatitis.

Conditions

• Seborrheic Dermatitis

Interventions

Type	Name	Description
DRUG	Elidel
DRUG	Ketoconazole Cream

Timeline

• Start date: 2007-05-07
• Primary completion: 2009-02-20
• Completion: 2009-02-27
• First posted: 2006-11-23
• Last updated: 2022-03-14
• Results posted: 2022-03-14

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study